title: Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
abstract: Naturally occurring antibodies directed against beta-amyloid (Abeta) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Abeta and Abeta(1-42) in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Abeta levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Abeta(1-42) levels. Antibodies against Abeta were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Abeta antibodies may modify Abeta and Abeta(1-42) levels, suggesting potential utility as a therapy for Alzheimer disease.
authors.affiliation: Department of Neurology, Philipps University Marburg, Germany. ydu@iupui.edu
authors.forename: Richard
authors.initials: R
authors.lastname: Dodel
authors.forename: Harald
authors.initials: H
authors.lastname: Hampel
authors.forename: Candan
authors.initials: C
authors.lastname: Depboylu
authors.forename: Suizhen
authors.initials: S
authors.lastname: Lin
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Sabine
authors.initials: S
authors.lastname: Schock
authors.forename: Steffi
authors.initials: S
authors.lastname: Jäckel
authors.forename: Xing
authors.initials: X
authors.lastname: Wei
authors.forename: Katharina
authors.initials: K
authors.lastname: Buerger
authors.forename: Christine
authors.initials: C
authors.lastname: Höft
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hemmer
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
authors.forename: Martin
authors.initials: M
authors.lastname: Farlow
authors.forename: Wolfgang H
authors.initials: WH
authors.lastname: Oertel
authors.forename: Norbert
authors.initials: N
authors.lastname: Sommer
authors.forename: Yansheng
authors.initials: Y
authors.lastname: Du
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D016229:Amyloid beta-Peptides / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology*; D000906:Antibodies / Q000097:blood / Q000134:cerebrospinal fluid / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy*; D010446:Peptide Fragments / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies; D016756:Immunoglobulins, Intravenous; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)